Abstract:BACKGROUND:Anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy has boosted the prognosis in advanced lung cancer. Meanwhile, accumulating cases showed the correlation between tuberculosis (TB) reactivation and anti-PD-1/PD-L1 immunotherapy. However, the safety and efficacy of anti-PD-1/PD-L1 immunotherapy for lung cancer complicated with TB infection could only be learned from real-world data.METHODS:We retrospectively analyzed 562 patients with advanced lung cancer who received anti-PD-1/PD-L1 immunotherapy at Shanghai Pulmonary Hospital from 2015 to 2019, including 13 patients with TB infection. Besides, relevant literature reviews were performed online to analyze the safety and efficacy of immunotherapy and to explore the appropriate treatment strategies in this specific population.RESULTS:In our cohort, the initiation of anti-PD-1/PD-L1 immunotherapy was from June 2015 to December 2019. Among them, 13 patients had TB infection prior to immunotherapy including 11 latent TB and 2 active TB, and all of them were treated with anti-PD-1 immunotherapy. Patients with active TB infection were treated with concurrent anti-TB and anti-PD-1 treatments, and the remaining received either mono-immunotherapy or combined immunotherapy. Neither reactivation of latent TB nor progression of active TB was monitored in our cohort during immunotherapy. Severe immune-related adverse events (irAEs) were diagnosed in two patients. Treatment strategies such as discontinuation of immunotherapy and administration of corticosteroids were provided timely, and one with latent TB infection got gradually improved, but the other one with active TB died quickly. The median progression-free survival (PFS) was 5.5 months for tumor immunotherapy in our cohort. However, the PFS of immunotherapy was merely 2.1 and 2.2 months in lung cancer patients with active TB infection.CONCLUSIONS:Immunotherapy is relatively safe for lung cancer patients complicated with previously treated latent TB, and the efficacy of immunotherapy in this specified population is not inferior to that in lung cancer patients without TB infection. TB screening before anti-PD-1/PD-L1 immunotherapy is strongly recommended, and irAEs should be monitored more cautiously in lung cancer patients with active TB infection.

Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway

CD11b(+) Dendritic Cell-Mediated Anti-Mycobacterium Tuberculosis Th1 Activation is Counterregulated by CD103(+) Dendritic Cells Via IL-10

The Safety and Efficacy of Immunotherapy with Anti-Programmed Cell Death 1 Monoclonal Antibody for Lung Cancer Complicated with Mycobacterium Tuberculosis Infection

Promoter methylation and increased expression of PD-L1 in patients with active tuberculosis

Absence of PD-L1 signaling hinders macrophage defense against Mycobacterium tuberculosis via upregulating STAT3/IL-6 pathway

PD-1/PD-L pathway inhibits M . tb -specific CD4 + T-cell functions and phagocytosis of macrophages in active tuberculosis

BATF Potentially Mediates Negative Regulation of PD-1/PD-Ls Pathway on T Cell Functions in Mycobacterium tuberculosis Infection

The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis

362P Integrative and Comparative Genomic Analysis and Immune Microenvironment Features of Lung Cancer Patients with Tuberculosis

MicroRNA-31 Mediated by Interferon Regulatory Factor 7 Signaling Facilitates Control of Mycobacterium Tuberculosis Infection

Advances in Molecular Mechanisms of Interaction Between Mycobacterium Tuberculosis and Lung Cancer: a Narrative Review

Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism

Immune Checkpoint Modulating T Cells and NK Cells Response to Mycobacterium Tuberculosis Infection

Mesenchymal-epithelial Transition Factor Regulates Monocyte Function During Mycobacterial Infection Via Indoleamine 2,3-Dioxygenase

Expressions of Programmed Death-1 and Programmed Death Ligand on the Surface of Peripheral Blood Lymphocytes in Patients with Tuberculosis

TLR1/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage.

Tumor PD-L1 Engages Myeloid PD-1 to Suppress Type I Interferon to Impair Cytotoxic T Lymphocyte Recruitment

Cd4(+)Cd25(+)Foxp3(+) Regulatory T Cells Suppress Mycobacterium Tuberculosis Immunity in Patients with Active Disease

Mucosal-associated Invariant T-Cell Function is Modulated by Programmed Death-1 Signaling in Patients with Active Tuberculosis

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

Mycobacterium Tuberculosis Culture Supernatant Induces Cancer Cell Apoptosis and Cell Cycle Arrest